The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

By J. Colombel, E. Loftus, W. Tremaine, L. Egan, W. Harmsen, C. Schleck, A. Zinsmeister, W. Sandborn. Gastroenterology, 2004

964 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/1f75e421e0c63c49f1b5832d1200847166f7baa4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. W. Sandborn
2. J. Colombel
3. S. Hanauer
4. G. Lichtenstein
5. B. Feagan
6. P. Rutgeerts
7. Bruce E. Sands
8. Markus F. Neurath

In Immunology

1. W. Sandborn
2. S. Hanauer
3. Stefan Schreiber

In Rheumatology

1. W. Sandborn
2. J. Colombel
3. Stefan Schreiber

Citations in the corpus

• The safety and side effects of monoclonal antibodies (2010, background): “pdf">infliximab (Remicade; Centocor Ortho Biotech) was generally well tolerated among patients with Crohn's diseas”
• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “The Mayo Clinic practice and Edinburgh series confirmed the relatively rare occurrence of malignancy.”
• Risk factors for opportunistic infections in patients with inflammatory bowel disease. (2008, neutral): “Indeterminate colitis, n (%) 4 (4) 6 (3)”
• Infliximab for induction and maintenance therapy for ulcerative colitis. (2005, result): “The safety findings in these studies were similar to the data reported in clinical studies of infliximab in patients with Crohn's disease, [15,16,30-32] in cohort studies, [33,34] and in post-marketing surveillance.”